Business Wire

Kantar Named a Strong Performer in Customer Analytics Report by Independent Research Firm

Share

Kantar, the world’s leading data-driven analytics and brand consulting company today celebrates its inclusion as a Strong Performer in The Forrester Wave™: Customer Analytics Service Providers, Q3 2021 report.

The Forrester Wave states:

  • Kantar “excels at customer retention analytics, showcasing the ability to define and predict ’silent churn’, a particularly challenging problem for retailers.”
  • The provider also excels at customer lifetime value analysis and pricing analytics, having transformed a hospitality giant’s loyalty points program.
  • Kantar’s client satisfaction is “very high”, and as a result so is client retention.
  • Kantar scored among the highest in the execution roadmap criterion.

According to Forrester, Kantar received strong referrals from referenced clients stating, “Several client references have long-term relationships with the provider, with one noting: ‘We look at them as a tough leader. They bring the best of the best to the table.’ Enterprises that want to understand their customers quantitatively and qualitatively should consider partnering with Kantar.”

Appreciating the recognition Chris Petranto, Global Head of Kantar Analytics commented “Since the launch of the Analytics Practice in 2018 we have been relentlessly focused on helping clients develop the deepest possible understanding of their customers. To be recognized in a Forrester Wave and receive a Strong Performer rating, in our opinion, further validates our impact on helping businesses grow with speed and profitability.”

The Forrester Wave™: Customer Analytics Service Providers, Q3 2021 report can be found at Download The Forrester Wave™: Customer Analytics Service Providers, Q3 2021 (kantar.com) More information about Kantar’s advanced analytics capabilities can be found at Customer Analytics (kantar.com)

-end-

About Kantar: Kantar is the world’s leading data, insights and consulting company. We have a complete, unique and rounded understanding of how people think, feel and act; globally and locally in over 90 markets. By combining the deep expertise of our people, our data resources and benchmarks, our innovative analytics and technology, we help our clients understand people and inspire growth.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Caroline Taylor, Director, AxiCom on behalf of Kantar
Caroline.taylor@Axicom.com
+353 86 778 9810

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Aesyra Demonstrates Significant Sleep Bruxism Reduction in Clinical Study26.1.2026 10:00:00 EET | Press release

Aesyra SA, a Swiss medtech company developing innovative digital therapeutics for dental and sleep-related disorders, today announced the successful completion of its clinical investigation evaluating the efficacy and safety of AesyBite™ Active, an intelligent oral appliance designed to treat and prevent sleep bruxism through biofeedback. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126533019/en/ AesyBite Custom smart nightguard by Aesyra SA. The clinical investigation demonstrated that AesyBite™ Active achieved a statistically significant and clinically meaningful reduction in sleep bruxism activity, exceeding the predefined performance target. Strong and robust clinical outcomes In the study (Identifier: NCT06153810), involving 26 adult patients with confirmed sleep bruxism, activation of the AesyBite Active biofeedback system resulted in a 60.6% reduction in total sleep bruxism duration per hour compared to baseline

Franklin Templeton Aligns Alternative Credit Firms Under BSP Brand26.1.2026 09:58:00 EET | Press release

Franklin Templeton’s US and European alternative credit businesses, Benefit Street Partners and Alcentra, have now aligned under an updated Benefit Street Partners (BSP) brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260123270080/en/ David Manlowe, CEO of Benefit Street Partners The move is the final step in BSP and Alcentra’s integration – two pioneering alternative credit firms that Franklin Templeton acquired in 2019 and 2022, respectively – and reflects increasing investor demand for a specialist global credit platform with expertise across the full spectrum of the asset class. A refreshed logo and new website domain accompany the brand alignment, and from this week Alcentra branded funds start to take on the BSP name.1 Overall, Franklin Templeton’s alternative credit platform – which also includes direct lender Apera – is on track to exceed $100 billion in AUM in 2026. According to new research also published tod

Syngenta and Statkraft Sign Five-Year Virtual Power Purchase Agreement26.1.2026 09:00:00 EET | Press release

Syngenta, one of the world’s biggest agricultural innovation companies, and Statkraft, a leading provider of innovative green energy solutions in Europe, have signed a virtual power purchase agreement (vPPA) covering Syngenta’s CP & Seeds operations for a period of five years. The volume amounts to 125 GWh per year and a total of 625 GWh of green electricity by the end of the contract in 2030. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260125701845/en/ Syngenta and Statkraft sign five-year virtual power purchase agreement With the vPPA, Statkraft is supporting Syngenta in advancing its sustainability strategy through the purchase of renewable energy. "This is Syngenta's first vPPA, marking a pivotal step in our decarbonization strategy," said Rachel Stenson Bugnon, Global Head CP Sourcing at Syngenta. "This tailored approach allows us to make meaningful progress toward our carbon reduction targets for Syngenta AG while m

Samsung Epis Holdings Reports Fourth Quarter and Fiscal Year 2025 Financial Results26.1.2026 09:00:00 EET | Press release

Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced financial results for the fourth quarter and fiscal year 2025. “We are very pleased to report strong year-to-date sales growth in our first financial results following the spin-off. Our organic growth has been driven by solid performance across our biosimilars portfolio," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We are continuing to make meaningful progress in our regulatory and commercial milestones with our existing biosimilars portfolio, while strategically investing in our future pipeline with a disciplined, long-term approach. We aim to drive sustainable growth and create long-term value for our shareholders, so that we can remain committed to improving patient access worldwide.” Samsung Bioepis Fourth Quarter & Fiscal Year 2025 Results In the fourth quarter of 2025, Samsung Bioepis achieved a

Merz Therapeutics Submits Application to the European Medicines Agency for New Indication of XEOMIN ® in Pediatric Spasticity26.1.2026 09:00:00 EET | Press release

Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that it has completed the regulatory submission for XEOMIN® (incobotulinumtoxinA) for the treatment of spasticity of the lower and upper limb in children and adolescents aged 2–17 years in the European Union (EU) and European Economic Area (EEA). If approved, the indication would expand access to an established botulinum neurotoxin therapy for some of the youngest and most vulnerable patients across Europe. Spasticity is a common and often debilitating condition in children and adolescents with certain neurological conditions, leading to increased muscle tone that can significantly limit movement, function and independence. One of the most common underlying causes of spasticity in children is cerebral palsy (CP), the most frequent motor disability in childhood, with spastic forms accounting for approximately 80% of all cases. In more severe cases, spasticity associated with CP can also affect spe

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye